SCYNEXIS, Inc. Discontinued Operation, Tax Effect of Discontinued Operation
SCYNEXIS, Inc. (SCYX) reported Discontinued Operation, Tax Effect of Discontinued Operation of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation · last filed 2017-03-13
- SCYNEXIS, Inc. discontinued operation, tax effect of discontinued operation for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. discontinued operation, tax effect of discontinued operation for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. discontinued operation, tax effect of discontinued operation for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. discontinued operation, tax effect of discontinued operation for the quarter ending 2014-12-31 was $257.00K.
- SCYNEXIS, Inc. discontinued operation, tax effect of discontinued operation for fiscal 2016 was $0.00.
- SCYNEXIS, Inc. discontinued operation, tax effect of discontinued operation for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- SCYNEXIS, Inc. discontinued operation, tax effect of discontinued operation for fiscal 2014 was $1.17M.
| Period end | Discontinued Operation, Tax Effect of Discontinued Operation 3 month | Discontinued Operation, Tax Effect of Discontinued Operation 6 month | Discontinued Operation, Tax Effect of Discontinued Operation 9 month | Discontinued Operation, Tax Effect of Discontinued Operation 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-13 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $0.00 derived: sum of 2 quarters · filed 2017-03-13 | $0.00 10-K · filed 2017-03-13 | |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-13 | $0.00 10-Q · filed 2015-11-13 | ||
| 2015-03-31 | $0.00 8-K · filed 2015-10-30 | $257.00K derived: sum of 2 quarters · filed 2017-03-13 | $595.00K derived: sum of 3 quarters · filed 2017-03-13 | |
| 2014-12-31 | $257.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $595.00K derived: sum of 2 quarters · filed 2017-03-13 | $1.17M 10-K · filed 2017-03-13 | |
| 2014-09-30 | $338.00K 10-Q · filed 2015-11-13 | $909.00K 10-Q · filed 2015-11-13 | ||
| 2014-03-31 | $313.00K 8-K · filed 2015-10-30 | |||
| 2013-12-31 | $575.00K 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |